Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uterine Cervical Neoplasms | 24 | 2023 | 2038 | 4.480 |
Why?
|
Carcinoma, Endometrioid | 11 | 2024 | 275 | 4.110 |
Why?
|
Endometrial Neoplasms | 22 | 2024 | 1381 | 3.990 |
Why?
|
Uterine Neoplasms | 16 | 2024 | 1424 | 3.230 |
Why?
|
Ovarian Neoplasms | 23 | 2024 | 4903 | 3.220 |
Why?
|
Vulvar Neoplasms | 6 | 2024 | 266 | 3.020 |
Why?
|
Adenocarcinoma, Mucinous | 10 | 2024 | 523 | 2.840 |
Why?
|
Papillomavirus Infections | 12 | 2024 | 1639 | 2.530 |
Why?
|
Adenocarcinoma | 18 | 2023 | 6360 | 2.490 |
Why?
|
Carcinoma in Situ | 7 | 2024 | 784 | 2.420 |
Why?
|
Endometrial Hyperplasia | 3 | 2024 | 102 | 2.360 |
Why?
|
Leiomyosarcoma | 7 | 2023 | 426 | 2.280 |
Why?
|
Immunohistochemistry | 27 | 2024 | 11063 | 1.820 |
Why?
|
Endometrium | 6 | 2023 | 406 | 1.790 |
Why?
|
Smooth Muscle Tumor | 4 | 2023 | 65 | 1.730 |
Why?
|
Placenta | 5 | 2024 | 1726 | 1.510 |
Why?
|
Precancerous Conditions | 3 | 2023 | 980 | 1.470 |
Why?
|
Ovarian Cysts | 2 | 2022 | 108 | 1.440 |
Why?
|
Sex Cord-Gonadal Stromal Tumors | 2 | 2022 | 117 | 1.360 |
Why?
|
Pathology, Clinical | 4 | 2022 | 374 | 1.320 |
Why?
|
Carcinoma | 9 | 2023 | 2326 | 1.240 |
Why?
|
Hysterectomy | 10 | 2024 | 863 | 1.210 |
Why?
|
Tumor Suppressor Protein p53 | 8 | 2024 | 2952 | 1.090 |
Why?
|
Placenta Accreta | 2 | 2024 | 242 | 1.090 |
Why?
|
Menorrhagia | 2 | 2016 | 59 | 1.030 |
Why?
|
Matrix Attachment Region Binding Proteins | 2 | 2016 | 48 | 1.020 |
Why?
|
Endometriosis | 4 | 2023 | 873 | 1.010 |
Why?
|
beta Catenin | 4 | 2024 | 1048 | 0.920 |
Why?
|
Adenosarcoma | 3 | 2021 | 36 | 0.910 |
Why?
|
Keratin-17 | 1 | 2024 | 26 | 0.910 |
Why?
|
Antigens, Differentiation | 3 | 2018 | 920 | 0.890 |
Why?
|
Neoplasm Staging | 21 | 2024 | 11217 | 0.870 |
Why?
|
GATA3 Transcription Factor | 1 | 2024 | 163 | 0.850 |
Why?
|
Female | 120 | 2024 | 396660 | 0.840 |
Why?
|
SOXB1 Transcription Factors | 1 | 2024 | 283 | 0.790 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 4 | 2019 | 934 | 0.790 |
Why?
|
Placenta Previa | 1 | 2024 | 125 | 0.790 |
Why?
|
Placenta Diseases | 1 | 2023 | 199 | 0.740 |
Why?
|
Vulvar Diseases | 1 | 2021 | 64 | 0.730 |
Why?
|
Endodermal Sinus Tumor | 1 | 2021 | 53 | 0.720 |
Why?
|
Myofibroma | 1 | 2021 | 45 | 0.710 |
Why?
|
Leiomyoma | 2 | 2023 | 644 | 0.700 |
Why?
|
Carcinoma, Verrucous | 1 | 2020 | 26 | 0.690 |
Why?
|
Sarcoma, Endometrial Stromal | 2 | 2019 | 92 | 0.690 |
Why?
|
Trophoblasts | 2 | 2023 | 223 | 0.670 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2021 | 219 | 0.660 |
Why?
|
Neoplasm Invasiveness | 10 | 2024 | 3611 | 0.650 |
Why?
|
Authorship | 1 | 2022 | 289 | 0.650 |
Why?
|
DNA Polymerase II | 1 | 2019 | 103 | 0.650 |
Why?
|
Myometrium | 2 | 2016 | 174 | 0.630 |
Why?
|
DNA Mismatch Repair | 3 | 2022 | 431 | 0.610 |
Why?
|
Observer Variation | 7 | 2024 | 2616 | 0.600 |
Why?
|
Humans | 124 | 2024 | 767040 | 0.590 |
Why?
|
Papillomaviridae | 7 | 2022 | 1139 | 0.570 |
Why?
|
Endometrial Stromal Tumors | 2 | 2018 | 46 | 0.560 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2023 | 529 | 0.560 |
Why?
|
Biopsy | 12 | 2021 | 6777 | 0.550 |
Why?
|
Endometrial Ablation Techniques | 1 | 2016 | 5 | 0.540 |
Why?
|
Chorionic Villi | 1 | 2016 | 53 | 0.540 |
Why?
|
Diagnosis, Differential | 12 | 2024 | 12986 | 0.530 |
Why?
|
Neoplasms, Glandular and Epithelial | 2 | 2018 | 488 | 0.530 |
Why?
|
Receptors, Estrogen | 3 | 2023 | 2252 | 0.530 |
Why?
|
Ovary | 4 | 2023 | 965 | 0.520 |
Why?
|
Forkhead Transcription Factors | 1 | 2023 | 1626 | 0.520 |
Why?
|
Breast | 4 | 2020 | 1972 | 0.520 |
Why?
|
Receptors, Progesterone | 2 | 2023 | 1159 | 0.520 |
Why?
|
Carcinoma, Ductal, Breast | 4 | 2019 | 1097 | 0.510 |
Why?
|
Soft Tissue Neoplasms | 2 | 2022 | 1162 | 0.490 |
Why?
|
Carcinoma, Lobular | 2 | 2019 | 480 | 0.490 |
Why?
|
Uterus | 4 | 2024 | 661 | 0.490 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.490 |
Why?
|
Dysmenorrhea | 1 | 2016 | 107 | 0.470 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2024 | 4049 | 0.470 |
Why?
|
Adult | 45 | 2024 | 223317 | 0.470 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2015 | 68 | 0.460 |
Why?
|
Mutation, Missense | 1 | 2023 | 2592 | 0.450 |
Why?
|
Middle Aged | 50 | 2024 | 223233 | 0.450 |
Why?
|
Vulva | 3 | 2023 | 84 | 0.450 |
Why?
|
Appendiceal Neoplasms | 1 | 2016 | 155 | 0.440 |
Why?
|
Pre-Eclampsia | 1 | 2023 | 1255 | 0.440 |
Why?
|
Prognosis | 18 | 2023 | 29963 | 0.430 |
Why?
|
Biopsy, Needle | 2 | 2015 | 1615 | 0.420 |
Why?
|
Disease-Free Survival | 7 | 2021 | 6844 | 0.410 |
Why?
|
Specimen Handling | 3 | 2024 | 706 | 0.410 |
Why?
|
Biological Products | 1 | 2022 | 948 | 0.410 |
Why?
|
Cervix Uteri | 6 | 2022 | 575 | 0.400 |
Why?
|
Aged | 37 | 2024 | 171319 | 0.400 |
Why?
|
Mutation | 8 | 2023 | 30211 | 0.390 |
Why?
|
Breast Neoplasms | 10 | 2020 | 21178 | 0.390 |
Why?
|
Aged, 80 and over | 18 | 2024 | 59548 | 0.390 |
Why?
|
DNA Mutational Analysis | 4 | 2022 | 4114 | 0.380 |
Why?
|
Predictive Value of Tests | 11 | 2024 | 15424 | 0.360 |
Why?
|
Hemangioma | 1 | 2016 | 727 | 0.360 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2013 | 260 | 0.350 |
Why?
|
Evidence-Based Medicine | 2 | 2021 | 3700 | 0.350 |
Why?
|
Pregnancy | 10 | 2024 | 30238 | 0.350 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2022 | 2183 | 0.340 |
Why?
|
Gynecology | 4 | 2024 | 534 | 0.330 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2006 | 0.330 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 7435 | 0.330 |
Why?
|
Colonic Neoplasms | 1 | 2021 | 2535 | 0.320 |
Why?
|
Awards and Prizes | 2 | 2023 | 365 | 0.310 |
Why?
|
Adenocarcinoma, Clear Cell | 2 | 2022 | 218 | 0.300 |
Why?
|
Progesterone | 1 | 2013 | 752 | 0.300 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2016 | 957 | 0.300 |
Why?
|
Lymph Node Excision | 5 | 2023 | 1267 | 0.300 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 904 | 0.300 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2024 | 705 | 0.300 |
Why?
|
Stromal Cells | 1 | 2013 | 1335 | 0.290 |
Why?
|
PTEN Phosphohydrolase | 2 | 2024 | 1119 | 0.290 |
Why?
|
Candidiasis | 1 | 2010 | 366 | 0.280 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2022 | 9410 | 0.280 |
Why?
|
Transcription Factors | 3 | 2023 | 12158 | 0.280 |
Why?
|
Necrosis | 3 | 2022 | 1614 | 0.270 |
Why?
|
Candida albicans | 1 | 2010 | 376 | 0.270 |
Why?
|
Intraoperative Care | 2 | 2021 | 768 | 0.270 |
Why?
|
Pelvic Neoplasms | 2 | 2022 | 249 | 0.270 |
Why?
|
Pancreatic Cyst | 1 | 2010 | 372 | 0.260 |
Why?
|
MutS Homolog 2 Protein | 2 | 2019 | 200 | 0.260 |
Why?
|
Enterocolitis, Necrotizing | 1 | 2010 | 328 | 0.260 |
Why?
|
Cell Differentiation | 2 | 2013 | 11657 | 0.250 |
Why?
|
Cystadenocarcinoma, Serous | 2 | 2021 | 480 | 0.240 |
Why?
|
Trophoblastic Tumor, Placental Site | 1 | 2024 | 21 | 0.230 |
Why?
|
Retrospective Studies | 27 | 2024 | 81659 | 0.230 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2022 | 2509 | 0.230 |
Why?
|
PAX2 Transcription Factor | 1 | 2024 | 86 | 0.230 |
Why?
|
Brachytherapy | 3 | 2021 | 1220 | 0.220 |
Why?
|
Frozen Sections | 2 | 2021 | 153 | 0.220 |
Why?
|
Thrombospondins | 1 | 2024 | 196 | 0.220 |
Why?
|
World Health Organization | 2 | 2020 | 1327 | 0.220 |
Why?
|
Education, Distance | 2 | 2024 | 260 | 0.210 |
Why?
|
Databases, Protein | 2 | 2016 | 390 | 0.210 |
Why?
|
Algorithms | 3 | 2019 | 14098 | 0.210 |
Why?
|
Myxosarcoma | 1 | 2022 | 11 | 0.200 |
Why?
|
Canada | 4 | 2022 | 2127 | 0.200 |
Why?
|
Leiomyomatosis | 1 | 2022 | 69 | 0.200 |
Why?
|
Proteomics | 1 | 2016 | 3913 | 0.200 |
Why?
|
Infarction | 1 | 2023 | 247 | 0.200 |
Why?
|
Computational Biology | 1 | 2013 | 3567 | 0.190 |
Why?
|
Pelvic Exenteration | 1 | 2021 | 22 | 0.190 |
Why?
|
Yolk Sac | 1 | 2021 | 79 | 0.180 |
Why?
|
Consensus | 2 | 2022 | 3207 | 0.180 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 3530 | 0.180 |
Why?
|
Endopeptidases | 1 | 2024 | 762 | 0.180 |
Why?
|
Carcinosarcoma | 1 | 2021 | 108 | 0.170 |
Why?
|
Fibrosarcoma | 1 | 2022 | 313 | 0.170 |
Why?
|
Young Adult | 9 | 2024 | 59980 | 0.170 |
Why?
|
Uterine Rupture | 1 | 2020 | 67 | 0.170 |
Why?
|
Mucin-6 | 1 | 2019 | 15 | 0.170 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2021 | 734 | 0.170 |
Why?
|
Sensitivity and Specificity | 4 | 2021 | 14672 | 0.170 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 1 | 2020 | 78 | 0.160 |
Why?
|
Receptor, erbB-2 | 2 | 2021 | 2599 | 0.160 |
Why?
|
Pathology, Surgical | 1 | 2020 | 147 | 0.160 |
Why?
|
Cell Nucleus | 3 | 2020 | 2875 | 0.160 |
Why?
|
Myofibroblasts | 1 | 2021 | 230 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 219 | 0.160 |
Why?
|
Serine Endopeptidases | 1 | 2024 | 1027 | 0.160 |
Why?
|
Lymphatic Metastasis | 4 | 2022 | 2900 | 0.160 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2019 | 101 | 0.150 |
Why?
|
Mentors | 1 | 2024 | 672 | 0.150 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2023 | 3552 | 0.150 |
Why?
|
Fibroadenoma | 1 | 2018 | 42 | 0.150 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2020 | 195 | 0.150 |
Why?
|
Phyllodes Tumor | 1 | 2018 | 55 | 0.150 |
Why?
|
Cicatrix | 1 | 2024 | 798 | 0.150 |
Why?
|
Tumor Burden | 3 | 2021 | 1903 | 0.140 |
Why?
|
Nucleic Acid Hybridization | 1 | 2019 | 1305 | 0.140 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 52 | 0.140 |
Why?
|
Societies, Medical | 4 | 2023 | 3964 | 0.140 |
Why?
|
Colorectal Neoplasms | 2 | 2019 | 6966 | 0.140 |
Why?
|
Chromogranins | 1 | 2017 | 160 | 0.140 |
Why?
|
Conization | 1 | 2016 | 18 | 0.140 |
Why?
|
Neprilysin | 2 | 2018 | 487 | 0.140 |
Why?
|
Risk Assessment | 7 | 2024 | 24299 | 0.130 |
Why?
|
Electrosurgery | 1 | 2016 | 53 | 0.130 |
Why?
|
Keratin-20 | 1 | 2016 | 31 | 0.130 |
Why?
|
Physicians, Women | 1 | 2022 | 516 | 0.130 |
Why?
|
Mucin-2 | 1 | 2016 | 50 | 0.130 |
Why?
|
Mitotic Index | 1 | 2016 | 160 | 0.130 |
Why?
|
GTP-Binding Protein alpha Subunits, Gs | 1 | 2017 | 194 | 0.130 |
Why?
|
Disease Progression | 4 | 2019 | 13646 | 0.130 |
Why?
|
Ribonuclease III | 1 | 2017 | 271 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2017 | 361 | 0.120 |
Why?
|
Reference Standards | 1 | 2019 | 1011 | 0.120 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2023 | 1788 | 0.120 |
Why?
|
Ontario | 1 | 2016 | 403 | 0.120 |
Why?
|
Mastectomy, Segmental | 1 | 2020 | 974 | 0.120 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12536 | 0.120 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 343 | 0.120 |
Why?
|
Physicians | 2 | 2023 | 4593 | 0.120 |
Why?
|
Cesarean Section | 1 | 2024 | 1419 | 0.120 |
Why?
|
Immediate-Early Proteins | 1 | 2017 | 444 | 0.120 |
Why?
|
Treatment Outcome | 6 | 2021 | 65295 | 0.120 |
Why?
|
Neoplasms | 2 | 2020 | 22350 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6513 | 0.120 |
Why?
|
DEAD-box RNA Helicases | 1 | 2017 | 385 | 0.120 |
Why?
|
Monitoring, Intraoperative | 1 | 2021 | 947 | 0.120 |
Why?
|
International Cooperation | 1 | 2020 | 1434 | 0.110 |
Why?
|
Reproducibility of Results | 5 | 2024 | 20169 | 0.110 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2017 | 562 | 0.110 |
Why?
|
RNA, Viral | 1 | 2022 | 2867 | 0.110 |
Why?
|
DNA, Viral | 1 | 2020 | 2201 | 0.110 |
Why?
|
Cell Shape | 1 | 2014 | 372 | 0.110 |
Why?
|
Human papillomavirus 11 | 1 | 2013 | 14 | 0.110 |
Why?
|
Human papillomavirus 6 | 1 | 2013 | 16 | 0.110 |
Why?
|
Progesterone Congeners | 1 | 2013 | 43 | 0.110 |
Why?
|
Gene Dosage | 1 | 2017 | 1211 | 0.110 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2013 | 95 | 0.110 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 2040 | 0.100 |
Why?
|
Carcinoma, Renal Cell | 2 | 2022 | 3186 | 0.100 |
Why?
|
Cell Size | 1 | 2014 | 624 | 0.100 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2017 | 615 | 0.100 |
Why?
|
Uterine Cervical Diseases | 1 | 2013 | 75 | 0.100 |
Why?
|
Adenoma | 1 | 2023 | 2155 | 0.100 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1396 | 0.100 |
Why?
|
In Situ Hybridization | 1 | 2016 | 1892 | 0.100 |
Why?
|
Metaplasia | 1 | 2013 | 326 | 0.100 |
Why?
|
Lymphocytosis | 1 | 2012 | 121 | 0.090 |
Why?
|
Mesenteric Artery, Superior | 1 | 2011 | 96 | 0.090 |
Why?
|
Hemorrhage | 1 | 2023 | 3464 | 0.090 |
Why?
|
Kidney Neoplasms | 2 | 2022 | 4282 | 0.090 |
Why?
|
Hemangioendothelioma | 1 | 2011 | 112 | 0.090 |
Why?
|
Microfilament Proteins | 1 | 2016 | 1130 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2023 | 3667 | 0.090 |
Why?
|
Neoadjuvant Therapy | 2 | 2020 | 2902 | 0.090 |
Why?
|
Mitosis | 1 | 2016 | 1176 | 0.090 |
Why?
|
Stomach Neoplasms | 1 | 2021 | 1481 | 0.090 |
Why?
|
Nephrectomy | 2 | 2012 | 928 | 0.090 |
Why?
|
Hemangiosarcoma | 1 | 2012 | 214 | 0.090 |
Why?
|
Treatment Failure | 1 | 2016 | 2658 | 0.080 |
Why?
|
Cystadenoma, Serous | 1 | 2010 | 99 | 0.080 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2013 | 391 | 0.080 |
Why?
|
Vaccination | 1 | 2022 | 3434 | 0.080 |
Why?
|
Sequence Analysis, DNA | 1 | 2020 | 4780 | 0.080 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2019 | 1900 | 0.080 |
Why?
|
Education, Medical, Graduate | 1 | 2022 | 2420 | 0.080 |
Why?
|
Case-Control Studies | 2 | 2017 | 22254 | 0.080 |
Why?
|
Time Factors | 3 | 2017 | 40154 | 0.080 |
Why?
|
Phenotype | 3 | 2017 | 16718 | 0.080 |
Why?
|
Portal Vein | 1 | 2011 | 437 | 0.080 |
Why?
|
Terminology as Topic | 1 | 2016 | 1540 | 0.080 |
Why?
|
DNA Copy Number Variations | 1 | 2017 | 2047 | 0.080 |
Why?
|
Kidney Glomerulus | 1 | 2011 | 571 | 0.080 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2012 | 594 | 0.080 |
Why?
|
Premenopause | 1 | 2013 | 1039 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2013 | 1836 | 0.070 |
Why?
|
Intestinal Perforation | 1 | 2010 | 254 | 0.070 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2020 | 3370 | 0.070 |
Why?
|
Peritonitis | 1 | 2010 | 368 | 0.070 |
Why?
|
Genital Neoplasms, Female | 1 | 2012 | 535 | 0.070 |
Why?
|
Public Health | 1 | 2020 | 2681 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2015 | 1621 | 0.070 |
Why?
|
Membrane Proteins | 1 | 2024 | 7868 | 0.070 |
Why?
|
Epithelial Cells | 2 | 2020 | 3698 | 0.070 |
Why?
|
DNA | 1 | 2020 | 7210 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 18063 | 0.070 |
Why?
|
Kidney | 2 | 2012 | 7063 | 0.070 |
Why?
|
Clinical Competence | 1 | 2022 | 4859 | 0.060 |
Why?
|
Survival Rate | 3 | 2021 | 12823 | 0.060 |
Why?
|
Pancreatectomy | 1 | 2010 | 825 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2015 | 2843 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3464 | 0.060 |
Why?
|
Vagina | 2 | 2022 | 849 | 0.060 |
Why?
|
Risk | 1 | 2016 | 9606 | 0.060 |
Why?
|
Gene Expression Profiling | 2 | 2017 | 9532 | 0.060 |
Why?
|
Cell Proliferation | 2 | 2017 | 10455 | 0.060 |
Why?
|
Databases, Factual | 1 | 2019 | 8068 | 0.060 |
Why?
|
Central Nervous System Neoplasms | 1 | 2012 | 928 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2023 | 5859 | 0.050 |
Why?
|
Adolescent | 3 | 2023 | 89046 | 0.050 |
Why?
|
Lymphoma | 1 | 2012 | 1896 | 0.050 |
Why?
|
Pancreatic Neoplasms | 2 | 2011 | 5446 | 0.050 |
Why?
|
Fumarate Hydratase | 1 | 2022 | 55 | 0.050 |
Why?
|
DNA-Binding Proteins | 1 | 2019 | 9612 | 0.050 |
Why?
|
Rupture | 1 | 2023 | 444 | 0.050 |
Why?
|
Groin | 1 | 2021 | 106 | 0.050 |
Why?
|
Proteins | 1 | 2016 | 6001 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39317 | 0.050 |
Why?
|
Pathology | 1 | 2024 | 270 | 0.040 |
Why?
|
Cohort Studies | 5 | 2022 | 41718 | 0.040 |
Why?
|
Gestational Age | 1 | 2010 | 3618 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2023 | 8535 | 0.040 |
Why?
|
Infant, Premature | 1 | 2010 | 2125 | 0.040 |
Why?
|
Injections, Intraperitoneal | 1 | 2020 | 411 | 0.040 |
Why?
|
Atherosclerosis | 2 | 2012 | 3418 | 0.040 |
Why?
|
Diagnostic Self Evaluation | 1 | 2021 | 228 | 0.040 |
Why?
|
Male | 8 | 2023 | 364203 | 0.040 |
Why?
|
Fertility | 1 | 2023 | 771 | 0.040 |
Why?
|
Preoperative Period | 1 | 2020 | 564 | 0.040 |
Why?
|
Feedback | 1 | 2022 | 797 | 0.040 |
Why?
|
Cysteine | 1 | 2022 | 896 | 0.040 |
Why?
|
DNA Helicases | 1 | 2023 | 854 | 0.040 |
Why?
|
Vaginal Smears | 1 | 2020 | 505 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 13650 | 0.040 |
Why?
|
North America | 1 | 2021 | 1287 | 0.040 |
Why?
|
Multiple Sclerosis | 1 | 2012 | 3229 | 0.040 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2019 | 249 | 0.030 |
Why?
|
United States | 3 | 2023 | 72971 | 0.030 |
Why?
|
Risk Factors | 3 | 2019 | 74886 | 0.030 |
Why?
|
Sepsis | 1 | 2010 | 2605 | 0.030 |
Why?
|
Child | 1 | 2024 | 80771 | 0.030 |
Why?
|
Digestive System Surgical Procedures | 1 | 2020 | 584 | 0.030 |
Why?
|
Lymphatic Vessels | 1 | 2019 | 356 | 0.030 |
Why?
|
Europe | 1 | 2021 | 3432 | 0.030 |
Why?
|
Oncogenes | 1 | 2019 | 1232 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2015 | 545 | 0.030 |
Why?
|
Blood Vessels | 1 | 2019 | 1110 | 0.030 |
Why?
|
Periodicals as Topic | 1 | 2024 | 1465 | 0.030 |
Why?
|
Inflammation | 1 | 2012 | 10869 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4855 | 0.020 |
Why?
|
Paracentesis | 1 | 2012 | 99 | 0.020 |
Why?
|
ROC Curve | 1 | 2018 | 3618 | 0.020 |
Why?
|
Ascites | 1 | 2012 | 336 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2010 | 26396 | 0.020 |
Why?
|
Sex Factors | 1 | 2022 | 10622 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2023 | 5794 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2013 | 36582 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 54886 | 0.020 |
Why?
|
Hypolipidemic Agents | 1 | 2012 | 609 | 0.020 |
Why?
|
Registries | 1 | 2024 | 8351 | 0.020 |
Why?
|
Constriction, Pathologic | 1 | 2011 | 1104 | 0.020 |
Why?
|
Mammography | 1 | 2019 | 2431 | 0.020 |
Why?
|
Transfection | 1 | 2015 | 5753 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3431 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3797 | 0.020 |
Why?
|
Research Design | 1 | 2022 | 6210 | 0.020 |
Why?
|
RNA Interference | 1 | 2015 | 2829 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8732 | 0.020 |
Why?
|
Heterozygote | 1 | 2012 | 2794 | 0.020 |
Why?
|
Abdominal Pain | 1 | 2012 | 1069 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2012 | 1319 | 0.020 |
Why?
|
Creatinine | 1 | 2011 | 1916 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12069 | 0.020 |
Why?
|
Fibrosis | 1 | 2011 | 2078 | 0.010 |
Why?
|
Postmenopause | 1 | 2012 | 2518 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 26325 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2015 | 8628 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 17097 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10582 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2019 | 9108 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2015 | 12790 | 0.010 |
Why?
|
Prevalence | 1 | 2012 | 15851 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15925 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2012 | 6573 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 21526 | 0.010 |
Why?
|
Hypertension | 1 | 2012 | 8615 | 0.010 |
Why?
|
Signal Transduction | 1 | 2015 | 23621 | 0.010 |
Why?
|
Infant | 1 | 2011 | 36485 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2011 | 20741 | 0.000 |
Why?
|